Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668339 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
A Phase 2 study, sponsored by Arcturus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 581
- Enrollment target
NCT04668339 is a Phase 2 study that was terminated before completion, run by Arcturus Therapeutics. The registered enrollment target is 581 participants.
The verdict
NCT04668339, a Phase 2 study, was terminated before completion, sponsored by Arcturus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 581 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older
Interventions
- BIOLOGICAL ARCT-021 single dose priming
- BIOLOGICAL ARCT-021 two lower dose priming
- BIOLOGICAL ARCT-021 two higher dose priming
- BIOLOGICAL Placebo (two doses), priming
- BIOLOGICAL Randomized booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668339
The ClinicalTrials.gov registry entry for NCT04668339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcturus Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ARCT-021 single dose priming is the first listed.
NCT04668339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668339 about?
NCT04668339 is a clinical study titled "A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults". This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose...
What is the current status of trial NCT04668339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 581 participants. The study started on 2021-01-07. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04668339?
The interventions under investigation include: ARCT-021 single dose priming (BIOLOGICAL), ARCT-021 two lower dose priming (BIOLOGICAL), ARCT-021 two higher dose priming (BIOLOGICAL), Placebo (two doses), priming (BIOLOGICAL), Randomized booster (BIOLOGICAL).
Who is sponsoring clinical trial NCT04668339?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.